Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Podcast Host of De Bruggenbouwers, shared on LinkedIn:
“The debates on weight-based dosing of pembrolizumab, which can save money, have led to the publication of a Dutch guideline on de-escalation strategies and off-label use.
Here I give some background, context and share my thoughts on the way forward.”